Radiomics nomogram for preoperative differentiation of early-stage serous borderline ovarian tumors and serous malignant ovarian tumors

被引:1
|
作者
Yu, Xinping [1 ]
Zou, Yuwei [2 ]
Wang, Lei [1 ]
Yang, Hongjuan [1 ]
Jiao, Jinwen [1 ]
Yu, Haiyang [3 ]
Zhang, Shuai [3 ]
机构
[1] Qingdao Univ, Dept Obstet, Affiliated Hosp, Qingdao, Peoples R China
[2] Qingdao Univ, Dept Pathol, Affiliated Hosp, Qingdao, Peoples R China
[3] Qingdao Univ, Dept Radiol, Affiliated Hosp, Qingdao, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2024年 / 13卷
关键词
ovarian tumors; multidetector computed tomography; radiomics; nomogram; preoperative differentiation; EPIDIDYMIS PROTEIN 4; CANCER; FEATURES; MRI; DIAGNOSIS;
D O I
10.3389/fonc.2023.1269589
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: This study aimed to construct a radiomics nomogram and validate its performance in the preoperative differentiation between early-stage (I and II) serous borderline ovarian tumors (SBOTs) and serous malignant ovarian tumors (SMOTs). Methods: Data were collected from 80 patients with early-stage SBOTs and 102 with early-stage SMOTs (training set: n = 127; validation set: n = 55). Univariate and multivariate analyses were performed to identify the independent clinicoradiological factors. A radiomics signature model was constructed using radiomics features extracted from multidetector computed tomography images of the venous phase, in which the least absolute shrinkage and selection operator regression was employed to lessen the dimensionality of the data and choose the radiomics features. A nomogram model was established by combining independent clinicoradiological factors with the radiomics signature. The performance of nomogram calibration, discrimination, and clinical usefulness was evaluated using training and validation sets. Results: In terms of clinicoradiological characteristics, age (p = 0.001), the diameter of the solid component (p = 0.009), and human epididymis protein 4 level (p < 0.001) were identified as the independent risk factors of SMOT, for which the area under the curves (AUCs) were calculated to be 0.850 and 0.836 in the training and validation sets, respectively. Nine features were finally selected to construct the radiomics signature model, which exhibited AUCs of 0.879 and 0.826 for the training and validation sets, respectively. The nomogram model demonstrated considerable calibration and discrimination with AUCs of 0.940 and 0.909 for the training and validation sets, respectively. The nomogram model displayed more prominent clinical usefulness than the clinicoradiological and radiomics signature models according to the decision curve analysis. Conclusions: The nomogram model can be employed as an individualized preoperative non-invasive tool for differentiating early-stage SBOTs from SMOTs.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] MDCT-Based Radiomics Features for the Differentiation of Serous Borderline Ovarian Tumors and Serous Malignant Ovarian Tumors
    Yu, Xin-ping
    Wang, Lei
    Yu, Hai-yang
    Zou, Yu-wei
    Wang, Chang
    Jiao, Jin-wen
    Hong, Hao
    Zhang, Shuai
    [J]. CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 329 - 336
  • [2] MORPHOLOGY OF OVARIAN SEROUS BORDERLINE TUMORS
    KARSELADZE, AI
    [J]. ARKHIV PATOLOGII, 1989, 51 (03) : 28 - 34
  • [3] Nomogram to predict recurrence in patients with early- and advanced-stage mucinous and serous borderline ovarian tumors
    Bendifallah, Sofiane
    Ballester, Marcos
    Uzan, Catherine
    Fauvet, Raffaele
    Morice, Philippe
    Darai, Emile
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2014, 211 (06) : 637.e1 - 637.e6
  • [4] RECURRENCES IN OVARIAN SEROUS BORDERLINE TUMORS (SBT)
    STEINMETZ, JC
    SILVA, EG
    ELNAGGAR, A
    GERSHENSON, DW
    [J]. LABORATORY INVESTIGATION, 1990, 62 (01) : A95 - A95
  • [5] Ovarian serous borderline tumors: The Citadel defended
    Kurman, RJ
    Seidman, JD
    [J]. HUMAN PATHOLOGY, 2000, 31 (11) : 1439 - 1440
  • [6] THE CHARACTERISTICS OF OVARIAN SEROUS TUMORS OF BORDERLINE MALIGNANCY
    唐敏一
    连利娟
    刘彤华
    [J]. 中华医学杂志(英文版), 1980, (07) : 459 - 464
  • [7] Assessing the landscape of ovarian serous borderline tumors
    Messini, Irini
    Doulgeraki, Triada
    Chrysanthakis, Dimitris
    Yiannou, Petros
    Gavresea, Theofani
    Papadimitriou, Christos
    Panoskaltsis, Theodoros
    Voulgaris, Zannis
    Vlachos, Athanassios
    Pavlakis, Kitty
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (03) : 572 - 578
  • [8] The molecular pathology of ovarian serous borderline tumors
    Malpica, A.
    Wong, K. -K.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 : 16 - 19
  • [9] Ovarian serous borderline tumors: The citadel defended
    Kempson, RL
    Hendrickson, MR
    [J]. HUMAN PATHOLOGY, 2000, 31 (05) : 525 - 526
  • [10] THE CHARACTERISTICS OF OVARIAN SEROUS TUMORS OF BORDERLINE MALIGNANCY
    TANG, MY
    LIAN, LJ
    LIU, TH
    [J]. CHINESE MEDICAL JOURNAL, 1980, 93 (07) : 459 - 464